Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
Body mass index
Primary progressive multiple sclerosis
Smoking
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
02
07
2021
accepted:
06
08
2021
revised:
30
07
2021
pubmed:
16
8
2021
medline:
23
2
2022
entrez:
15
8
2021
Statut:
ppublish
Résumé
Smoking and obesity are recognized modifiable risk factors associated with a higher MS incidence, but their impact on physical and cognitive disability worsening is less clear. To investigate the impact of smoking and obesity on disability worsening in primary progressive MS (PPMS). We used data from INFORMS (clinicaltrials.gov identifier: NCT00731692), a large randomized-controlled trial in PPMS to compare significant worsening on the EDSS, T25FW, NHPT, and PASAT between smokers and non-smokers, and between BMI groups, at 12, 24, and 33 months of follow-up. We investigated the association of smoking and BMI at screening and the risk of disability worsening with logistic regression models. Smokers had significantly higher EDSS scores throughout the trial. EDSS was not significantly different between BMI categories. No other outcome measure was significantly different between smokers and non-smokers and between BMI categories throughout the trial. Neither smoking status nor BMI were associated with significant worsening on any outcome measure at any time point during follow-up. Despite the known effects on MS incidence, smoking and BMI were not associated with the risk of physical and cognitive disability worsening over 3 years in this well-characterized PPMS trial cohort.
Sections du résumé
BACKGROUND
BACKGROUND
Smoking and obesity are recognized modifiable risk factors associated with a higher MS incidence, but their impact on physical and cognitive disability worsening is less clear.
OBJECTIVE
OBJECTIVE
To investigate the impact of smoking and obesity on disability worsening in primary progressive MS (PPMS).
METHODS
METHODS
We used data from INFORMS (clinicaltrials.gov identifier: NCT00731692), a large randomized-controlled trial in PPMS to compare significant worsening on the EDSS, T25FW, NHPT, and PASAT between smokers and non-smokers, and between BMI groups, at 12, 24, and 33 months of follow-up. We investigated the association of smoking and BMI at screening and the risk of disability worsening with logistic regression models.
RESULTS
RESULTS
Smokers had significantly higher EDSS scores throughout the trial. EDSS was not significantly different between BMI categories. No other outcome measure was significantly different between smokers and non-smokers and between BMI categories throughout the trial. Neither smoking status nor BMI were associated with significant worsening on any outcome measure at any time point during follow-up.
CONCLUSION
CONCLUSIONS
Despite the known effects on MS incidence, smoking and BMI were not associated with the risk of physical and cognitive disability worsening over 3 years in this well-characterized PPMS trial cohort.
Identifiants
pubmed: 34392376
doi: 10.1007/s00415-021-10750-z
pii: 10.1007/s00415-021-10750-z
doi:
Banques de données
ClinicalTrials.gov
['NCT00731692']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1663-1669Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Koch M, Mostert J, Heersema D, De Keyser J (2007) Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci 255:35–41. https://doi.org/10.1016/j.jns.2007.01.067
doi: 10.1016/j.jns.2007.01.067
pubmed: 17331540
Vukusic S, Confavreux C (2007) Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 20:269–274. https://doi.org/10.1097/WCO.0b013e32812583ad
doi: 10.1097/WCO.0b013e32812583ad
pubmed: 17495619
Hernán MA, Olek MJ, Ascherio A (2001) Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 154:69–74
doi: 10.1093/aje/154.1.69
Handel AE, Williamson AJ, Disanto G et al (2011) Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE 6:e16149. https://doi.org/10.1371/journal.pone.0016149
doi: 10.1371/journal.pone.0016149
pubmed: 21249154
pmcid: 3020969
Cortese M, Riise T, Bjørnevik K et al (2018) Body size and physical exercise, and the risk of multiple sclerosis. Mult Scler 24:270–278. https://doi.org/10.1177/1352458517699289
doi: 10.1177/1352458517699289
pubmed: 28287051
Gianfrancesco MA, Stridh P, Rhead B et al (2017) Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology 88:1623–1629. https://doi.org/10.1212/WNL.0000000000003849
doi: 10.1212/WNL.0000000000003849
pubmed: 28356466
pmcid: 5405763
Hernán MA, Jick SS, Logroscino G et al (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128:1461–1465. https://doi.org/10.1093/brain/awh471
doi: 10.1093/brain/awh471
pubmed: 15758034
Healy BC, Ali EN, Guttmann CRG et al (2009) Smoking and disease progression in multiple sclerosis. Arch Neurol 66:858–864. https://doi.org/10.1001/archneurol.2009.122
doi: 10.1001/archneurol.2009.122
pubmed: 19597087
pmcid: 2754172
Koch M, van Harten A, Uyttenboogaart M, De Keyser J (2007) Cigarette smoking and progression in multiple sclerosis. Neurology 69:1515–1520. https://doi.org/10.1212/01.wnl.0000277658.78381.db
doi: 10.1212/01.wnl.0000277658.78381.db
pubmed: 17923613
Javizian O, Metz LM, Deighton S, Koch MW (2017) Smoking does not influence disability accumulation in primary progressive multiple sclerosis. Eur J Neurol 24:624–630. https://doi.org/10.1111/ene.13262
doi: 10.1111/ene.13262
pubmed: 28239937
Lublin F, Miller DH, Freedman MS et al (2016) Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387:1075–1084. https://doi.org/10.1016/S0140-6736(15)01314-8
doi: 10.1016/S0140-6736(15)01314-8
pubmed: 26827074
Motl RW, Cohen JA, Benedict R et al (2017) Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler 23:704–710. https://doi.org/10.1177/1352458517690823
doi: 10.1177/1352458517690823
pubmed: 28206828
pmcid: 5405807
Feys P, Lamers I, Francis G et al (2017) The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler 23:711–720. https://doi.org/10.1177/1352458517690824
doi: 10.1177/1352458517690824
pubmed: 28206826
pmcid: 5405844
R Core Team (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
Barros AJD, Hirakata VN (2003) Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3:21. https://doi.org/10.1186/1471-2288-3-21
doi: 10.1186/1471-2288-3-21
pubmed: 14567763
pmcid: 521200
Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L (2011) Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler 17:788–793. https://doi.org/10.1177/1352458511399610
doi: 10.1177/1352458511399610
pubmed: 21372120
Hedström AK, Olsson T, Alfredsson L (2016) Body mass index during adolescence, rather than childhood, is critical in determining MS risk. Mult Scler 22:878–883. https://doi.org/10.1177/1352458515603798
doi: 10.1177/1352458515603798
pubmed: 26362895
Briggs FBS, Thompson NR, Conway DS (2019) Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 30:9–16. https://doi.org/10.1016/j.msard.2019.01.045
doi: 10.1016/j.msard.2019.01.045
pubmed: 30711764
Fitzgerald KC, Salter A, Tyry T et al (2020) Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. Mult Scler 26:976–986. https://doi.org/10.1177/1352458519845836
doi: 10.1177/1352458519845836
pubmed: 31079537
Filippatou AG, Lambe J, Sotirchos ES et al (2020) Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis. Mult Scler 26:843–854. https://doi.org/10.1177/1352458519900942
doi: 10.1177/1352458519900942
pubmed: 32297826
pmcid: 7293552
Mowry EM, Azevedo CJ, McCulloch CE et al (2018) Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology 91:e2256–e2264. https://doi.org/10.1212/WNL.0000000000006644
doi: 10.1212/WNL.0000000000006644
pubmed: 30429274
pmcid: 6329329
Owji M, Ashraf-Ganjouei A, Sahraian MA et al (2019) The relationship between cognitive function and body mass index in multiple sclerosis patients. Mult Scler Relat Disord 32:37–40. https://doi.org/10.1016/j.msard.2019.04.024
doi: 10.1016/j.msard.2019.04.024
pubmed: 31030017
Cortese M, Munger KL, Martínez-Lapiscina EH et al (2020) Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology 94:e1950–e1960. https://doi.org/10.1212/WNL.0000000000009371
doi: 10.1212/WNL.0000000000009371
pubmed: 32300060
pmcid: 7274920
Kutzelnigg A, Lucchinetti CF, Stadelmann C et al (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712. https://doi.org/10.1093/brain/awh641
doi: 10.1093/brain/awh641
pubmed: 16230320
Frischer JM, Bramow S, Dal-Bianco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189. https://doi.org/10.1093/brain/awp070
doi: 10.1093/brain/awp070
pubmed: 19339255
pmcid: 2677799
Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8:647–656. https://doi.org/10.1038/nrneurol.2012.168
doi: 10.1038/nrneurol.2012.168
pubmed: 23007702
Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782
doi: 10.1093/brain/awg081
Leray E, Yaouanq J, Le Page E et al (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913. https://doi.org/10.1093/brain/awq076
doi: 10.1093/brain/awq076
pubmed: 20423930
pmcid: 2892936